<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Nifty Pharma has fallen by 12.8 per cent so far this year, with Natco Pharma and Granules India leading the plunge ...

In India, it is the pharma sector that fits the bill. For a simple reason. While the Trump regime will make noises about tariffs on Indian pharma imports, the reality is that, given the poor state of ...

With an overview of the Nifty 50 to Donald Trump's tariff, Experts recommend eight stocks to buy or sell on Wednesday — 9 ...

Natco Pharma on Tuesday shared a legal ... ratio of 7.87 against a price-to-book (P/B) value of 2.04. Earnings per share (EPS) stood at 98.90 with a return on equity (RoE) of 25.89.

"Subject to the foregoing, the Company has decided to price the product at INR 15,900 ... filed against the suit patent in India. Share of Natco Pharma gained 1.29% to close at Rs 776.30 on ...

The recovery in Titan share price came just a day after the stock touched its 52-week low of Rs 2,947.55. In the morning session, Titan shares climbed to a high of Rs 3,222, providing some relief to ...

Natco Pharma has decided to price Risdiplam, indicated for the treatment of rare genetic disorder Spinal Muscular Atrophy (SMA), at₹15,900. In an update on the legal proceedings on the ...

Shares of Adani Ports and Special Economic Zone recovered sharply from Monday's low (April 7) after the company announced the commencement of operations at the Colombo West International Terminal ...